How has neoantigen discovery transformed cancer vaccines?

Question

Accepted Answer

Neoantigen Discovery Has Revolutionised Cancer Vaccines by Enabling Personalised Treatments

The advent of neoantigen discovery has fundamentally transformed cancer vaccines by shifting the paradigm from broad antigen targeting to highly personalised approaches. This advancement leverages sophisticated algorithms to predict which tumour-derived peptides will elicit an immune response when presented by a patient's unique HLA molecules, thereby enabling the creation of bespoke vaccines. The prevailing consensus within the field now clearly indicates that the future of cancer vaccines lies in private neoantigens, moving away from previously explored shared antigens.
Shift from Shared to Private Neoantigens

For decades, the pursuit of effective cancer vaccines was hampered by the reliance on shared antigens, which are overexpressed self-antigens present in many tumour types. However, these antigens proved to be weakly immunogenic and often failed to elicit a robust T-cell response against established cancers. The breakthrough came with the ability to sequence a patient's tumour and identify private neoantigens – unique mutant peptides arising from tumour-specific genetic alterations. This personalised approach, driven by algorithms that predict peptide binding to individual HLA molecules, has become the cornerstone of modern cancer vaccine development, with a clear consensus that "shared antigens are out; private neoantigens are in."
Algorithmic Prediction of Immunogenic Peptides

The development of advanced algorithms has been critical in translating neoantigen discovery into clinical application. These computational tools analyse tumour DNA and RNA sequences to predict which mutated peptides are likely to bind effectively to a patient's specific Human Leukocyte Antigen (HLA) molecules. This prediction is essential because the presentation of these peptides by HLA molecules on tumour cells is how T cells recognise and target cancerous cells. By identifying these specific binding peptides, researchers can design vaccines that are tailored to the unique mutational landscape of an individual's tumour, thereby maximising the potential for a targeted immune response.
Importance of Delivery Vehicle and Danger Signals

Beyond identifying the target neoantigens, the way in which these antigens are delivered has also been a significant area of advancement. It has become clear that a neoantigen peptide delivered alone is often ignored by the immune system. However, when encapsulated within delivery vehicles, such as lipid nanoparticles (LNPs), and combined with innate immune agonists, these peptides can trigger a potent immune alert. The location and method of delivery are now considered paramount, with LNPs that migrate to lymph nodes and are efficiently processed by dendritic cells emerging as the current gold standard for vaccine formulation. This insight highlights that the efficacy of a cancer vaccine is critically dependent on its ability to generate a strong danger signal to the immune system.

Reading history

Hide →

This history is cleared when the page is closed.

How has neoantigen discovery transformed cancer vaccines?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends